Potential obesity breakthrough boosts Marcadia

Back to TopCommentsE-mailPrintBookmark and Share

Marcadia Biotech is now on the radar screen.

CEO Fritz French thinks the publication of the Carmel company’s research on obesity-fighting compounds by the major scientific journal *Nature Chemical Biology will grab attention of scientists and other drug companies around the world.“It gets us more exposure to large pharma companies collaborating down the road — on other things,” French said. The *Nature article involved Marcadia’s collaborative work with New Jersey-based drug giant Merck & Co. Inc. But the Carmel-based biotech firm has several other obesity and diabetes-fighting drugs in its pipeline.

“All of these things add to your credibility and image,” French said.

*Nature Chemical Biology is a sister publication of the widely known journal *Nature.

The *Nature article demonstrated the elimination of obesity in rodents in one week with an injection of Marcadia-developed molecules. The molecules, licensed from Indiana University, combine some of the protein sequence of two naturally occurring hormones that regulate blood sugar, glucagon and glucagon-like-peptide-1.

The novel combination had a big impact on the mice used in tests of the drug. Marcadia’s researchers found that a single injection of their best molecule in mice decreased body weight by 25 percent and fat mass by 42 percent after one week. Repeated treatment had even greater effect.

“The results that we saw in these animal models were unprecedented,” French said.

Marcadia and Merck will move the experimental molecules into human trials, which will cost hundreds of millions of dollars to take all the way to market. And it may not get there. Plenty of experimental drugs have shown great promise in animals only to fail in humans.

But the buzz about Marcadia’s potential breakthrough could help the company with future fund-raising needs. To date, the 3-year-old company has raised $16 million in venture capital.

It has 10 employees and works closely with researchers at IU, who toil under Marcadia co-founder Richard DiMarchi. DiMarchi and University of Cincinnati physician Matthias Tschöp were the co-lead authors of the *Nature article.

“It is an important milestone for the company to get this external validation,” French said. “We’ve been relatively under the radar of a lot of people until now.”•


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ